Aarey Drugs & Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 31, 2025, 8:22 pm

Market Cap	153 Cr.
Current Price	54.1
High / Low	75.8/31.3
Stock P/E	38.1
Book Value	47.8
Dividend Yield	0.00 %
ROCE	6.17 %
ROE	3.03 %
Face Value	10.0
PEG Ratio	-6.25

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Aarey Drugs & Pharmaceuticals Ltd

Competitors of Aarey Drugs & Pharmaceuticals Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	134 Cr.	95.0	247/84.3	26.0	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.27 Cr.	2.76	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	39.9 Cr.	53.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	41.1 Cr.	28.0	29.1/13.1	40.3	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,354.98 Cr	1,129.60		88.53	194.54	0.32%	16.70%	15.22%	6.19

All Competitor Stocks of Aarey Drugs & Pharmaceuticals Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	140.27	120.25	118.84	76.26	62.47	162.88	50.96	57.83	76.48	210.35	126.91	105.14	133.79
Expenses	137.21	118.38	117.93	71.99	60.94	160.36	49.62	55.99	73.78	211.79	125.73	101.42	131.59
Operating Profit	3.06	1.87	0.91	4.27	1.53	2.52	1.34	1.84	2.70	-1.44	1.18	3.72	2.20
OPM %	2.18%	1.56%	0.77%	5.60%	2.45%	1.55%	2.63%	3.18%	3.53%	-0.68%	0.93%	3.54%	1.64%
Other Income	0.13	1.13	0.85	-0.94	0.48	0.84	0.70	0.84	0.29	5.14	1.58	0.02	0.68
Interest	0.49	0.43	0.55	0.59	0.71	0.20	0.42	0.41	0.47	0.40	0.47	0.49	0.58
Depreciation	0.50	0.59	0.41	0.42	0.55	1.02	0.89	1.27	1.06	1.15	0.96	1.51	0.90
Profit before tax	2.20	1.98	0.80	2.32	0.75	2.14	0.73	1.00	1.46	2.15	1.33	1.74	1.40
Tax %	11.36%	137.88%	0.00%	9.05%	-33.33%	83.18%	0.00%	-22.00%	30.14%	-0.47%	6.77%	8.62%	48.57%
Net Profit	1.95	-0.76	0.80	2.12	1.00	0.36	0.72	1.23	1.02	2.15	1.24	1.60	0.72
EPS in Rs	0.77	-0.30	0.32	0.84	0.39	0.14	0.28	0.48	0.40	0.77	0.44	0.57	0.25

Last Updated: February 28, 2025, 4:01 pm

Below is a detailed analysis of the quarterly data for Aarey Drugs & Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 133.79 Cr.. The value appears strong and on an upward trend. It has increased from 105.14 Cr. (Sep 2024) to 133.79 Cr., marking an increase of 28.65 Cr..
For Expenses, as of Dec 2024, the value is 131.59 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 101.42 Cr. (Sep 2024) to 131.59 Cr., marking an increase of 30.17 Cr..
For Operating Profit, as of Dec 2024, the value is 2.20 Cr.. The value appears to be declining and may need further review. It has decreased from 3.72 Cr. (Sep 2024) to 2.20 Cr., marking a decrease of 1.52 Cr..
For OPM %, as of Dec 2024, the value is 1.64%. The value appears to be declining and may need further review. It has decreased from 3.54% (Sep 2024) to 1.64%, marking a decrease of 1.90%.
For Other Income, as of Dec 2024, the value is 0.68 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Sep 2024) to 0.68 Cr., marking an increase of 0.66 Cr..
For Interest, as of Dec 2024, the value is 0.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.49 Cr. (Sep 2024) to 0.58 Cr., marking an increase of 0.09 Cr..
For Depreciation, as of Dec 2024, the value is 0.90 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.51 Cr. (Sep 2024) to 0.90 Cr., marking a decrease of 0.61 Cr..
For Profit before tax, as of Dec 2024, the value is 1.40 Cr.. The value appears to be declining and may need further review. It has decreased from 1.74 Cr. (Sep 2024) to 1.40 Cr., marking a decrease of 0.34 Cr..
For Tax %, as of Dec 2024, the value is 48.57%. The value appears to be increasing, which may not be favorable. It has increased from 8.62% (Sep 2024) to 48.57%, marking an increase of 39.95%.
For Net Profit, as of Dec 2024, the value is 0.72 Cr.. The value appears to be declining and may need further review. It has decreased from 1.60 Cr. (Sep 2024) to 0.72 Cr., marking a decrease of 0.88 Cr..
For EPS in Rs, as of Dec 2024, the value is 0.25. The value appears to be declining and may need further review. It has decreased from 0.57 (Sep 2024) to 0.25, marking a decrease of 0.32.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:18 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	172	200	213	246	396	349	354	298	348	493	419	396	576
Expenses	170	198	212	245	386	342	347	294	344	481	411	391	571
Operating Profit	2	1	1	1	10	8	8	3	5	11	8	4	6
OPM %	1%	1%	1%	0%	2%	2%	2%	1%	1%	2%	2%	1%	1%
Other Income	0	2	3	3	3	3	4	7	7	3	3	7	7
Interest	1	1	1	2	4	2	2	2	2	2	3	4	2
Depreciation	1	1	1	1	1	1	1	1	1	2	2	2	5
Profit before tax	1	1	1	2	8	8	9	7	8	10	6	5	7
Tax %	27%	22%	23%	29%	31%	25%	27%	20%	21%	35%	37%	12%
Net Profit	1	1	1	1	5	6	7	6	7	7	4	5	6
EPS in Rs	0.39	0.62	0.65	0.77	3.02	2.64	2.80	2.48	2.78	2.58	1.49	1.67	2.03
Dividend Payout %	0%	0%	0%	0%	0%	0%	4%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	0.00%	0.00%	0.00%	400.00%	20.00%	16.67%	-14.29%	16.67%	0.00%	-42.86%	25.00%
Change in YoY Net Profit Growth (%)	0.00%	0.00%	0.00%	400.00%	-380.00%	-3.33%	-30.95%	30.95%	-16.67%	-42.86%	67.86%

Aarey Drugs & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	8%
5 Years:	10%
3 Years:	-1%
TTM:	20%

Compounded Profit Growth
10 Years:	14%
5 Years:	-7%
3 Years:	-15%
TTM:	-14%

Stock Price CAGR
10 Years:	16%
5 Years:	24%
3 Years:	15%
1 Year:	18%

Return on Equity
10 Years:	6%
5 Years:	4%
3 Years:	3%
Last Year:	3%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 2:24 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	17	17	17	17	18	23	23	23	23	25	25	28	28
Reserves	17	18	19	20	31	57	63	69	75	88	92	105	108
Borrowings	5	6	11	15	10	3	16	18	18	14	38	31	39
Other Liabilities	69	67	69	74	83	86	43	84	116	117	136	139	100
Total Liabilities	107	107	115	125	142	170	146	194	233	245	291	303	275
Fixed Assets	4	4	6	8	12	12	12	12	14	14	14	13	13
CWIP	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments	3	0	0	0	0	0	0	0	0	0	0	1	1
Other Assets	99	102	109	117	130	157	133	181	218	230	277	289	260
Total Assets	107	107	115	125	142	170	146	194	233	245	291	303	275

Below is a detailed analysis of the balance sheet data for Aarey Drugs & Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 28.00 Cr..
For Reserves, as of Sep 2024, the value is 108.00 Cr.. The value appears strong and on an upward trend. It has increased from 105.00 Cr. (Mar 2024) to 108.00 Cr., marking an increase of 3.00 Cr..
For Borrowings, as of Sep 2024, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 31.00 Cr. (Mar 2024) to 39.00 Cr., marking an increase of 8.00 Cr..
For Other Liabilities, as of Sep 2024, the value is 100.00 Cr.. The value appears to be improving (decreasing). It has decreased from 139.00 Cr. (Mar 2024) to 100.00 Cr., marking a decrease of 39.00 Cr..
For Total Liabilities, as of Sep 2024, the value is 275.00 Cr.. The value appears to be improving (decreasing). It has decreased from 303.00 Cr. (Mar 2024) to 275.00 Cr., marking a decrease of 28.00 Cr..
For Fixed Assets, as of Sep 2024, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
For CWIP, as of Sep 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
For Investments, as of Sep 2024, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
For Other Assets, as of Sep 2024, the value is 260.00 Cr.. The value appears to be declining and may need further review. It has decreased from 289.00 Cr. (Mar 2024) to 260.00 Cr., marking a decrease of 29.00 Cr..
For Total Assets, as of Sep 2024, the value is 275.00 Cr.. The value appears to be declining and may need further review. It has decreased from 303.00 Cr. (Mar 2024) to 275.00 Cr., marking a decrease of 28.00 Cr..

Notably, the Reserves (108.00 Cr.) exceed the Borrowings (39.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	-0	3	6	1	-20	1	3	5	0	-1	-3
Cash from Investing Activity +	2	-2	-3	-5	-1	-1	-1	-3	-3	0	-2
Cash from Financing Activity +	-1	-2	-2	4	23	-2	-2	-2	2	1	6
Net Cash Flow	0	-1	1	-1	2	-3	0	0	-0	1	1

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-3.00	-5.00	-10.00	-14.00	0.00	5.00	-8.00	-15.00	-13.00	-3.00	-30.00	-27.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	141	119	114	108	75	100	109	118	170	101	165	170
Inventory Days	16	10	7	3	5	16	23	21	20	11	26	33
Days Payable	146	119	117	108	71	84	40	98	120	86	115	123
Cash Conversion Cycle	11	9	5	3	9	32	92	42	69	26	76	80
Working Capital Days	64	62	68	61	44	72	94	121	110	76	118	132
ROCE %	4%	6%	7%	7%	22%	14%	12%	9%	10%	10%	6%	6%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	48.06%	50.03%	50.04%	50.04%	50.05%	50.04%	50.04%	50.04%	45.28%	45.28%	45.44%	44.80%
FIIs	4.23%	3.92%	3.98%	3.92%	3.92%	3.92%	3.94%	3.83%	3.40%	3.40%	2.75%	2.34%
Public	47.70%	46.04%	45.97%	46.04%	46.04%	46.03%	46.01%	46.12%	51.31%	51.32%	51.81%	52.86%
No. of Shareholders	17,565	17,777	17,649	17,785	17,699	17,538	16,086	15,269	16,843	16,179	16,676	16,288

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	1.84	1.49	2.72	2.79	2.48
Diluted EPS (Rs.)	1.84	1.49	2.72	2.79	2.80
Cash EPS (Rs.)	2.27	2.11	3.36	3.18	2.86
Book Value[Excl.RevalReserv]/Share (Rs.)	47.33	46.25	44.77	42.27	39.49
Book Value[Incl.RevalReserv]/Share (Rs.)	47.33	46.25	44.77	42.27	39.49
Revenue From Operations / Share (Rs.)	141.02	165.04	194.09	148.99	128.33
PBDIT / Share (Rs.)	4.07	4.12	5.52	4.98	4.24
PBIT / Share (Rs.)	3.46	3.50	4.74	4.59	3.86
PBT / Share (Rs.)	1.90	2.37	3.95	3.55	3.10
Net Profit / Share (Rs.)	1.67	1.49	2.58	2.79	2.48
PBDIT Margin (%)	2.88	2.49	2.84	3.34	3.30
PBIT Margin (%)	2.45	2.11	2.44	3.08	3.00
PBT Margin (%)	1.35	1.43	2.03	2.38	2.41
Net Profit Margin (%)	1.18	0.90	1.32	1.86	1.93
Return on Networth / Equity (%)	3.52	3.21	5.75	6.58	6.27
Return on Capital Employeed (%)	7.10	7.20	10.44	10.68	9.62
Return On Assets (%)	1.53	1.29	2.66	2.79	2.98
Long Term Debt / Equity (X)	0.02	0.03	0.00	0.00	0.00
Total Debt / Equity (X)	0.23	0.32	0.12	0.18	0.19
Asset Turnover Ratio (%)	1.33	1.56	2.06	1.63	1.77
Current Ratio (X)	0.58	1.61	1.74	1.65	1.81
Quick Ratio (X)	0.37	1.44	1.63	1.51	1.64
Inventory Turnover Ratio (X)	12.21	0.00	0.00	0.00	0.00
Interest Coverage Ratio (X)	2.61	3.65	7.01	4.79	5.56
Interest Coverage Ratio (Post Tax) (X)	2.07	2.32	4.27	3.68	4.25
Enterprise Value (Cr.)	155.10	97.10	119.06	71.62	48.49
EV / Net Operating Revenue (X)	0.39	0.23	0.24	0.20	0.16
EV / EBITDA (X)	13.59	9.29	8.50	6.15	4.89
MarketCap / Net Operating Revenue (X)	0.31	0.14	0.21	0.15	0.10
Price / BV (X)	0.94	0.51	0.92	0.54	0.33
Price / Net Operating Revenue (X)	0.31	0.14	0.21	0.15	0.10
EarningsYield	0.03	0.06	0.06	0.12	0.18

After reviewing the key financial ratios for Aarey Drugs & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 1.84. This value is below the healthy minimum of 5. It has increased from 1.49 (Mar 23) to 1.84, marking an increase of 0.35.
For Diluted EPS (Rs.), as of Mar 24, the value is 1.84. This value is below the healthy minimum of 5. It has increased from 1.49 (Mar 23) to 1.84, marking an increase of 0.35.
For Cash EPS (Rs.), as of Mar 24, the value is 2.27. This value is below the healthy minimum of 3. It has increased from 2.11 (Mar 23) to 2.27, marking an increase of 0.16.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 47.33. It has increased from 46.25 (Mar 23) to 47.33, marking an increase of 1.08.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 47.33. It has increased from 46.25 (Mar 23) to 47.33, marking an increase of 1.08.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 141.02. It has decreased from 165.04 (Mar 23) to 141.02, marking a decrease of 24.02.
For PBDIT / Share (Rs.), as of Mar 24, the value is 4.07. This value is within the healthy range. It has decreased from 4.12 (Mar 23) to 4.07, marking a decrease of 0.05.
For PBIT / Share (Rs.), as of Mar 24, the value is 3.46. This value is within the healthy range. It has decreased from 3.50 (Mar 23) to 3.46, marking a decrease of 0.04.
For PBT / Share (Rs.), as of Mar 24, the value is 1.90. This value is within the healthy range. It has decreased from 2.37 (Mar 23) to 1.90, marking a decrease of 0.47.
For Net Profit / Share (Rs.), as of Mar 24, the value is 1.67. This value is below the healthy minimum of 2. It has increased from 1.49 (Mar 23) to 1.67, marking an increase of 0.18.
For PBDIT Margin (%), as of Mar 24, the value is 2.88. This value is below the healthy minimum of 10. It has increased from 2.49 (Mar 23) to 2.88, marking an increase of 0.39.
For PBIT Margin (%), as of Mar 24, the value is 2.45. This value is below the healthy minimum of 10. It has increased from 2.11 (Mar 23) to 2.45, marking an increase of 0.34.
For PBT Margin (%), as of Mar 24, the value is 1.35. This value is below the healthy minimum of 10. It has decreased from 1.43 (Mar 23) to 1.35, marking a decrease of 0.08.
For Net Profit Margin (%), as of Mar 24, the value is 1.18. This value is below the healthy minimum of 5. It has increased from 0.90 (Mar 23) to 1.18, marking an increase of 0.28.
For Return on Networth / Equity (%), as of Mar 24, the value is 3.52. This value is below the healthy minimum of 15. It has increased from 3.21 (Mar 23) to 3.52, marking an increase of 0.31.
For Return on Capital Employeed (%), as of Mar 24, the value is 7.10. This value is below the healthy minimum of 10. It has decreased from 7.20 (Mar 23) to 7.10, marking a decrease of 0.10.
For Return On Assets (%), as of Mar 24, the value is 1.53. This value is below the healthy minimum of 5. It has increased from 1.29 (Mar 23) to 1.53, marking an increase of 0.24.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
For Total Debt / Equity (X), as of Mar 24, the value is 0.23. This value is within the healthy range. It has decreased from 0.32 (Mar 23) to 0.23, marking a decrease of 0.09.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.33. It has decreased from 1.56 (Mar 23) to 1.33, marking a decrease of 0.23.
For Current Ratio (X), as of Mar 24, the value is 0.58. This value is below the healthy minimum of 1.5. It has decreased from 1.61 (Mar 23) to 0.58, marking a decrease of 1.03.
For Quick Ratio (X), as of Mar 24, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 1.44 (Mar 23) to 0.37, marking a decrease of 1.07.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 12.21. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 23) to 12.21, marking an increase of 12.21.
For Interest Coverage Ratio (X), as of Mar 24, the value is 2.61. This value is below the healthy minimum of 3. It has decreased from 3.65 (Mar 23) to 2.61, marking a decrease of 1.04.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.07. This value is below the healthy minimum of 3. It has decreased from 2.32 (Mar 23) to 2.07, marking a decrease of 0.25.
For Enterprise Value (Cr.), as of Mar 24, the value is 155.10. It has increased from 97.10 (Mar 23) to 155.10, marking an increase of 58.00.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.39. This value is below the healthy minimum of 1. It has increased from 0.23 (Mar 23) to 0.39, marking an increase of 0.16.
For EV / EBITDA (X), as of Mar 24, the value is 13.59. This value is within the healthy range. It has increased from 9.29 (Mar 23) to 13.59, marking an increase of 4.30.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.31. This value is below the healthy minimum of 1. It has increased from 0.14 (Mar 23) to 0.31, marking an increase of 0.17.
For Price / BV (X), as of Mar 24, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.51 (Mar 23) to 0.94, marking an increase of 0.43.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.31. This value is below the healthy minimum of 1. It has increased from 0.14 (Mar 23) to 0.31, marking an increase of 0.17.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 23) to 0.03, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Aarey Drugs & Pharmaceuticals Ltd as of June 1, 2025 is: 45.03

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 1, 2025, Aarey Drugs & Pharmaceuticals Ltd is Overvalued by 16.77% compared to the current share price 54.10

Intrinsic Value of Aarey Drugs & Pharmaceuticals Ltd as of June 1, 2025 is: 42.29

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 1, 2025, Aarey Drugs & Pharmaceuticals Ltd is Overvalued by 21.83% compared to the current share price 54.10

Last 5 Year EPS CAGR: -6.09%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (58.62 cr) compared to borrowings (17.23 cr), indicating strong financial stability. The company has shown consistent growth in sales (343.08 cr) and profit (5.62 cr) over the years.	The stock has a low average ROCE of 9.42%, which may not be favorable. The stock has a high average Working Capital Days of 85.17, which may not be favorable. The stock has a high average Cash Conversion Cycle of 37.83, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarey Drugs & Pharmaceuticals Ltd:
1. Net Profit Margin: 1.18%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 7.1% (Industry Average ROCE: 16.7%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 3.52% (Industry Average ROE: 15.22%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 2.07
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.37
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 38.1 (Industry average Stock P/E: 88.53)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.23
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Aarey Drugs & Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 15/05/1990 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1990PLC056538 and registration number is 056538. Currently Company is involved in the business activities of Activities of commission agents dealing in wholesale trade inwood, paper, skin, leather and fur, fuel, petroleum products, chemicals, perfumery and cosmetics, glass, minerals, ores and metals. Company's Total Operating Revenue is Rs. 395.62 Cr. and Equity Capital is Rs. 28.05 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	E-34, M.I.D.C., Thane Maharashtra 401506	investorgrievance@aareydrugs.com http://www.aareydrugs.com

Management
Name	Position Held
Mr. Mihir R Ghatalia	Chairman & Managing Director
Mr. Nimit Rajesh Ghatalia	Executive Director
Ms. Bina Rajesh Ghatalia	Woman Director
Mr. Lalit Radhakrishna Tulsiani	Independent Director
Mr. Anil Mandal	Independent Director
Mr. Chetan K Mehta	Independent Director

FAQ

What is the intrinsic value of Aarey Drugs & Pharmaceuticals Ltd?

Aarey Drugs & Pharmaceuticals Ltd's intrinsic value (as of 01 June 2025) is ₹45.03 — 16.77% lower the current market price of 54.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 153 Cr. market cap, FY2025-2026 high/low of ₹75.8/31.3, reserves of 108 Cr, and liabilities of 275 Cr.

What is the Market Cap of Aarey Drugs & Pharmaceuticals Ltd?

The Market Cap of Aarey Drugs & Pharmaceuticals Ltd is 153 Cr..

What is the current Stock Price of Aarey Drugs & Pharmaceuticals Ltd as on 01 June 2025?

The current stock price of Aarey Drugs & Pharmaceuticals Ltd as on 01 June 2025 is 54.1.

What is the High / Low of Aarey Drugs & Pharmaceuticals Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Aarey Drugs & Pharmaceuticals Ltd stocks is ₹75.8/31.3.

What is the Stock P/E of Aarey Drugs & Pharmaceuticals Ltd?

The Stock P/E of Aarey Drugs & Pharmaceuticals Ltd is 38.1.

What is the Book Value of Aarey Drugs & Pharmaceuticals Ltd?

The Book Value of Aarey Drugs & Pharmaceuticals Ltd is 47.8.

What is the Dividend Yield of Aarey Drugs & Pharmaceuticals Ltd?

The Dividend Yield of Aarey Drugs & Pharmaceuticals Ltd is 0.00 %.

What is the ROCE of Aarey Drugs & Pharmaceuticals Ltd?

The ROCE of Aarey Drugs & Pharmaceuticals Ltd is 6.17 %.

What is the ROE of Aarey Drugs & Pharmaceuticals Ltd?

The ROE of Aarey Drugs & Pharmaceuticals Ltd is 3.03 %.

What is the Face Value of Aarey Drugs & Pharmaceuticals Ltd?

The Face Value of Aarey Drugs & Pharmaceuticals Ltd is 10.0.